hC Bioscience is a biopharmaceutical company pioneering tRNA-based protein editing therapies to address a broad spectrum of genetically defined diseases and cancers. Their proprietary platform focuses on engineering transfer RNA (tRNA) molecules to correct premature termination codons (PTCs), enabling the production of full-length, functional proteins from mutated genes. This approach offers a versatile and gene-agnostic solution to various genetic disorders. 

The company's pipeline includes lead programs targeting severe hemophilia A and Duchenne muscular dystrophy (DMD). In hemophilia A, hC Bioscience's anticodon engineered (ACE) tRNAs aim to restore functional Factor VIII protein production in patients with PTC-driven deficiencies. For DMD, their technology seeks to produce full-length dystrophin protein, addressing approximately 12% of cases caused by mutations leading to truncated proteins. Additionally, hC Bioscience is exploring oncology applications by restoring tumor suppressor functions and inducing proteome destabilization in cancer cells. 

United States

hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for tRNA drug products includes a variety of delivery approaches, with the goal of improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting cancer and rare diseases.

hC Bioscience

Company Details